07:55 AM EST, 03/07/2025 (MT Newswires) -- Astrazeneca ( AZN ) said Friday that results from a phase 3 trial of Imfinzi in combination with standard-of-care chemotherapy to treat certain gastric cancers met the primary endpoint of event-free survival.

Patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction cancers were treated with neoadjuvant Imfinzi in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel before surgery, followed by adjuvant Imfinzi in combination with chemotherapy, then Imfinzi monotherapy.

Astrazeneca ( AZN ) also said that for the secondary endpoint of overall survival, a "strong trend" was seen in the interim analysis that favors the Imfinzi-based regimen.

The adjunctive therapy more than doubled pathologic complete response rate in previously reported analysis of this trial in 2023, the company said.